financetom
Business
financetom
/
Business
/
Latham Group Slides After 2024 Revenue Outlook Lags Consensus View, Outweighing Surprise Q4 Profit
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Latham Group Slides After 2024 Revenue Outlook Lags Consensus View, Outweighing Surprise Q4 Profit
Mar 13, 2024 9:37 AM

12:01 PM EDT, 03/13/2024 (MT Newswires) -- Latham Group ( SWIM ) late Tuesday reported Q4 net income of $0.00 per diluted share compared with a $0.17 loss a year earlier.

Analysts polled by Capital IQ expected a $0.12 loss.

Revenue for the quarter ended Dec. 31 was $90.9 million, down from $107.9 million a year earlier.

Analysts expected $87 million.

For 2024, the residential swimming pool company is projecting revenue of $490 million to $520 million.

Analysts are looking for $520.7 million.

Latham shares recently were recently down about 8%, partially recovering from a more than 13% decline soon after Wednesday's opening bell.

Price: 3.02, Change: -0.26, Percent Change: -8.08

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Capricor Therapeutics' Biologics License Application for Deramiocel Accepted by FDA
Capricor Therapeutics' Biologics License Application for Deramiocel Accepted by FDA
Mar 10, 2025
10:45 AM EDT, 03/10/2025 (MT Newswires) -- Capricor Therapeutics' ( CAPR ) biologics license application for deramiocel to treat Duchenne muscular dystrophy cardiomyopathy was accepted and granted priority review by the US Food and Drug Administration, a Nippon Shinyaku subsidiary said Monday. Nippon Shinyaku and Capricor entered into an exclusive distribution agreement for deramiocel for the US in January 2022,...
Genmab Says Johnson & Johnson Declines Global License Option for HexaBody-CD38; Shares Fall
Genmab Says Johnson & Johnson Declines Global License Option for HexaBody-CD38; Shares Fall
Mar 10, 2025
10:58 AM EDT, 03/10/2025 (MT Newswires) -- Genmab ( GMAB ) said Monday that Johnson & Johnson ( JNJ ) has chosen not to exercise its option for a global license to develop, produce, and market HexaBody-CD38. Although the initial HexaBody-CD38 clinical data demonstrated strong efficacy, Genmab ( GMAB ) has decided not to proceed with further development after evaluating...
Knightscope Receives Contracts for Security Robots, Emergency Communication Devices
Knightscope Receives Contracts for Security Robots, Emergency Communication Devices
Mar 10, 2025
10:48 AM EDT, 03/10/2025 (MT Newswires) -- Knightscope ( KSCP ) said Monday it renewed four autonomous security robot subscription agreements, deployed seven autonomous security robots, and signed new sales contracts for 96 of its emergency communication devices. The security robot renewals were for customers in the healthcare, automotive lubricants, and logistics sectors, the company said. New deployments were for...
SunCar Gets Contract to Build Insurance Platform for Leapmotor
SunCar Gets Contract to Build Insurance Platform for Leapmotor
Mar 10, 2025
10:54 AM EDT, 03/10/2025 (MT Newswires) -- SunCar Technology Group ( SDA ) said Monday it has secured a contract to develop and operate an insurance management platform for electric vehicle maker Leapmotor. This contract transforms our relationship with Leapmotor from service provider to technology partner, said Chief Executive Officer Ye Zaichang. The system will be integrated into Leapmotor's mobile...
Copyright 2023-2026 - www.financetom.com All Rights Reserved